# US 10,117,911 B2 · Compositions and methods to treat herpes simplex virus infections > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,117,911 B2 - Document ID: US10117911B2 - Status: Granted - Kind: B2 - Application number: 15/167,204 - Filed: 2016-05-27 - Published: 2016-12-01 - Granted: 2018-11-06 - Earliest claimed: 2015-05-29 - Assignees: Agenovir Corporation - Applicants: Agenovir Corporation - Inventors: Stephen R. Quake; Jianbin Wang - Web page: https://patentgrep.com/patent/US10117911B2 ## CPC - A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases} - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - C12N 9/16: acting on ester bonds (3.1) - C12N 15/1133: {against herpetoviridae, e.g. HSV} - C12Y 301/00: Hydrolases acting on ester bonds (3.1) - C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR] - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12Y: ENZYMES ## Abstract Herpes simplex virus (HSV) including herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are a persistent cause of human disease with no known cure. Guided nuclease systems target specific regions of the HSV-1 and HSV-2 genomes, disrupting the virus' nucleic acid and rendering even latent viruses incapacitated. ## Claims ### Claim 1 A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising a vector encoding: a Cas9 endonuclease; and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9 endonuclease to the region of HSV nucleic acid. ### Claim 2 (depends on 1) The composition of claim 1, wherein the composition is configured to be administered transdermally. ### Claim 3 (depends on 1) The composition of claim 1, wherein the composition comprises a topical solution. ### Claim 4 (depends on 1) The composition of claim 1, wherein the composition is packaged for delivery to a human patient. ### Claim 5 (depends on 1) The composition of claim 1, wherein the portion of the guide RNA complementary to the origin of replication S (oriS) region of HSV nucleic acid has no match >60% within a human genome. ### Claim 6 (depends on 1) The composition of claim 1, wherein the vector comprises one selected from the group consisting of: retrovirus, lentivirus, adenovirus, herpesvirus, poxvirus, alphavirus, vaccinia virus, adeno-associated viruses, a plasmid, a nanoparticle, a cationic lipid, a cationic polymer, metallic nanoparticle, a nanorod, a liposome, microbubbles, a cell-penetrating peptide, and a liposphere. ### Claim 7 A method for treating a herpes simplex virus (HSV) infection, the method comprising: introducing into a cell of a host, (i) a vector encoding a Cas9 endonuclease and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, or (ii) a ribonucleoprotein that includes the Cas9 endonuclease and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, wherein the guide RNA is capable of directing the Cas9 endonuclease to the region of HSV nucleic acid. ### Claim 8 (depends on 7) The method of claim 7, further comprising transdermally administering the vector or ribonucleoprotein to the host. ### Claim 9 (depends on 8) The method of claim 8, wherein the transdermal administration comprises applying a topical solution comprising the vector or ribonucleoprotein. ### Claim 10 (depends on 7) The method of claim 7, wherein the host is a living human subject and the method is performed in vivo. ### Claim 11 (depends on 7) The method of claim 7, wherein the portion of the guide RNA complementary to the origin of replication S (oriS) region of HSV nucleic acid has no match >60% within a human genome. ### Claim 12 (depends on 7) The method of claim 7, wherein the vector comprises one selected from the group consisting of: retrovirus, lentivirus, adenovirus, herpesvirus, poxvirus, alphavirus, vaccinia virus, adeno-associated viruses, a plasmid, a nanoparticle, a cationic lipid, a cationic polymer, metallic nanoparticle, a nanorod, a liposome, microbubbles, a cell-penetrating peptide, and a liposphere. ### Claim 13 A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising a ribonucleoprotein, wherein the ribonucleoprotein comprises: a Cas9 endonuclease; and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9 endonuclease to the region of HSV nucleic acid. ### Claim 14 (depends on 13) The composition of claim 13, wherein the composition is configured to be administered transdermally. ### Claim 15 (depends on 13) The composition of claim 13, further comprising a pharmaceutically acceptable carrier for topical application to infected tissue. ### Claim 16 (depends on 13) The composition of claim 13, wherein the portion of the guide RNA complementary to the origin of replication S (oriS) region of HSV nucleic acid has no match >60% within a human genome. ### Claim 17 A composition for treatment of a herpes simplex virus (HSV) infection, the composition comprising: an mRNA encoding a Cas9 endonuclease; and a guide RNA having a portion complementary to an origin of replication S (oriS) region of HSV nucleic acid, the guide RNA capable of directing the Cas9endonuclease to the region of HSV nucleic acid. ### Claim 18 (depends on 17) The composition of claim 17, wherein the mRNA and the guide RNA are encapsulated in or complexed with a lipid nanoparticle. ### Claim 19 (depends on 17) The composition of claim 17, wherein the composition comprises a topical solution. ### Claim 20 (depends on 17) The composition of claim 17, wherein the portion of the guide RNA complementary to the origin of replication S (oriS) region of HSV nucleic acid has no match >60% within a human genome. ### Claim 21 (depends on 17) The composition of claim 17, wherein the mRNA and the guide RNA are encapsulated in or complexed with a lipid nanoparticle.